Sibannac Takes Majority Stake in Apollo Wellness Centers

What happened

Sibannac, Inc. holds a 51% majority interest in Apollo Wellness Centers, Inc., a joint venture with Doc-Rx.com, LLC formed under an agreement dated October 1, 2026. Apollo launches on Doc-Rx's existing telehealth and U.S.-made peptide platform and plans wellness clinics through licensing.

Confirmed

Global impact / market context

The 51% stake gives Sibannac control of Apollo without buying Doc-Rx, so Sibannac can direct clinic expansion while relying on a partner's operating telehealth platform. This limits what Sibannac must build itself but ties its wellness push to Doc-Rx's prescribing and pharmacy network, which means the partner's platform.

Analyst inference

The venture enters telehealth and peptide-based wellness, where clinics can add revenue through licensing rather than owning every site. For Sibannac, growth depends on standing up branded clinics and on Doc-Rx's compounding pharmacies and U.S. peptide supply, which means the manufacturing chain from raw material to finished product.

Analyst inference

What to watch

1. Apollo's stated main growth plan is to stand up wellness clinics under the Apollo Wellness Centers brand through a licensing model, so clinic openings and licensing deals are concrete milestones to track. Confirmed
2. The joint venture agreement sets out how Apollo is to earn revenue, so watch for disclosed revenue terms and whether licensing fees or clinic services become the main money source. Proposed
3. Because Apollo relies on Doc-Rx's telehealth clinicians and partner 503A compounding pharmacies, which are licensed facilities that mix prescriptions, any disruption in that supply chain would slow clinic growth and revenue. Analyst inference

Evidence

• accessnewswire.com